

Provider Notification of Retail Drug Policy Criteria Change			
Drug Impacted	Criteria Change	Effective Date	Formulary
Omisirge	Added coverage for the treatment of severe aplastic anemia (SAA) for members 6 years of age and older following reduced intensity conditioning therapy, per FDA label update.	2/22/2026	Essential
Padcev	Updated coverage for urothelial carcinoma in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmpb to align with NCCN and FDA label update.	2/22/2026	Essential Metallic
Revuforj	Added coverage for use in patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation, per FDA label update and NCCN. Documentation of NPM1 mutational status added for applicable submissions.	2/22/2026	Essential